Kheiron Medical Technologies
Helps radiologists detect breast cancer earlier using deep learning.
- B2B
- saas
- subscription
- health
- medical devices
- health platform
- biotechnology
- big data
- computer vision
- deep learning
- deep tech
- machine learning
- nanotech
- artificial intelligence
- biotechnology
- horizon europe
- dt and ls
- spinout
- core ai
- ai applications
- oncology
- ai agents
- drug development
- health it
- femtech
- ai drug discovery
- tech for hospitals and clinics
- tech for medical professionals
- techbio
- physician support tools
- medical diagnostics
- medical imaging
- techbio drug discovery
- clinical decision support
- ai for medical imaging
- radiology
- bia techbio uk
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| GBP | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (97 %) | 6744 % | (33 %) | 48 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (501419 %) | (3346 %) | (11022 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (443744 %) | (3024 %) | (10870 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates, Company filings or news article
Related Content
Kheiron Medical Technologies is a pioneering startup focused on transforming cancer diagnostics through the power of artificial intelligence (AI). The company specializes in developing AI solutions for radiology, particularly breast cancer screening. By leveraging deep learning—a type of AI that mimics the human brain to process data—Kheiron aims to help radiologists detect cancer earlier, thereby improving patient outcomes.
Kheiron primarily serves healthcare providers, including hospitals and clinics, with a strong focus on the National Health Service (NHS) in the UK. The company also has a growing presence in the U.S. market. Their clients are radiologists and medical professionals who benefit from enhanced diagnostic accuracy and efficiency.
Operating in the healthcare technology market, Kheiron addresses critical issues such as the radiology workforce crisis and the need for early cancer detection. The company’s flagship product is an AI platform that assists radiologists in identifying cancerous tissues in mammograms more accurately and quickly. This not only improves survival rates but also optimizes the workflow for radiologists, allowing them to focus on the most urgent cases.
Kheiron’s business model is based on a Software-as-a-Service (SaaS) approach. They offer their AI platform to healthcare providers on a subscription basis, generating recurring revenue. Additionally, they engage in partnerships and clinical studies to validate and improve their technology, further enhancing their market credibility.
Revenue is generated through subscription fees for their AI platform, and potentially through collaborations and partnerships with healthcare institutions and research organizations. Their innovative solutions have earned them accolades, including the Artificial Intelligence in Health and Care Award in 2020.
In summary, Kheiron Medical Technologies is at the forefront of AI-driven cancer diagnostics, providing advanced tools to healthcare providers to improve early detection and patient outcomes.
Keywords: AI, radiology, breast cancer, diagnostics, healthcare, deep learning, NHS, SaaS, early detection, medical technology.